EP0647133A4 - Zusammensetzungen und verfahren zur verbesserte arzneimittelabgabe. - Google Patents
Zusammensetzungen und verfahren zur verbesserte arzneimittelabgabe.Info
- Publication number
- EP0647133A4 EP0647133A4 EP93915319A EP93915319A EP0647133A4 EP 0647133 A4 EP0647133 A4 EP 0647133A4 EP 93915319 A EP93915319 A EP 93915319A EP 93915319 A EP93915319 A EP 93915319A EP 0647133 A4 EP0647133 A4 EP 0647133A4
- Authority
- EP
- European Patent Office
- Prior art keywords
- compositions
- methods
- drug delivery
- enhanced drug
- enhanced
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
- A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/541—Organic ions forming an ion pair complex with the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6957—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a device or a kit, e.g. stents or microdevices
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nanotechnology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Medical Informatics (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US89821992A | 1992-06-12 | 1992-06-12 | |
US898219 | 1992-06-12 | ||
US946393A | 1993-01-27 | 1993-01-27 | |
US9463 | 1993-01-27 | ||
PCT/US1993/005631 WO1993025197A1 (en) | 1992-06-12 | 1993-06-11 | Compositions and methods for enhanced drug delivery |
Publications (2)
Publication Number | Publication Date |
---|---|
EP0647133A1 EP0647133A1 (de) | 1995-04-12 |
EP0647133A4 true EP0647133A4 (de) | 1997-10-29 |
Family
ID=26679515
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EP93915319A Withdrawn EP0647133A4 (de) | 1992-06-12 | 1993-06-11 | Zusammensetzungen und verfahren zur verbesserte arzneimittelabgabe. |
Country Status (3)
Country | Link |
---|---|
EP (1) | EP0647133A4 (de) |
AU (1) | AU4534593A (de) |
WO (1) | WO1993025197A1 (de) |
Families Citing this family (64)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5744500A (en) | 1990-01-03 | 1998-04-28 | Teva Pharmaceutical Industries, Ltd. | Use of R-enantiomer of N-propargyl-1-aminoindan, salts, and compositions thereof |
US6610841B1 (en) | 1997-12-18 | 2003-08-26 | Gilead Sciences, Inc. | Nucleotide-based prodrugs |
ATE169930T1 (de) * | 1993-03-10 | 1998-09-15 | Magainin Pharma | Steroidderivate, pharmazeutische zusammensetzungen die sie enthalten und ihre verwendung als antibiotika oder desinfektionsmittel |
US5505715A (en) * | 1994-02-25 | 1996-04-09 | Bristol-Myers Squibb Company | Iontophoretic transdermal delivery of deoxyspergualin compounds |
US6468981B1 (en) | 1994-07-29 | 2002-10-22 | Emory University | Compositions and methods for targeting pharmaceutically active materials to cells containing androgen receptors |
US5840740A (en) * | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds and a method of treating infection using the aminosterol compounds |
US5856535A (en) * | 1994-08-18 | 1999-01-05 | Magainin Pharmaceuticals, Inc. | Aminosterol ester compounds |
FR2727117A1 (fr) * | 1994-11-18 | 1996-05-24 | Geffard Michel | Utilisation de conjugues de la polylysine pour la preparation de medicaments utiles dans le traitement des maladies neurodegeneratives et des affections degeneratives a caractere autoimmun |
TR199700878T1 (xx) † | 1995-03-02 | 1998-01-21 | R.P. Scherer Limited | Monamin oksidaz B inhibit�rleri i�eren farmakotik kompozisyonlar. |
US8071737B2 (en) | 1995-05-04 | 2011-12-06 | Glead Sciences, Inc. | Nucleic acid ligand complexes |
IT1285405B1 (it) * | 1995-06-06 | 1998-06-03 | Alza Corp | Modificazione di farmaci polipeptidici per accrescere il flusso per elettrotrasporto. |
US5747453A (en) * | 1995-06-06 | 1998-05-05 | Alza Corporation | Method for increasing the electrotransport flux of polypeptides |
US5847172A (en) * | 1995-06-07 | 1998-12-08 | Magainin Pharmaceuticals Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US5795885A (en) * | 1995-06-07 | 1998-08-18 | Magainin Pharmaceuticals Inc. | Method of inhibiting profileration of cells by administering an aminosterol compound |
US5994336A (en) * | 1995-06-07 | 1999-11-30 | Magainin Pharmaceuticals Inc. | Method of inhibiting proliferation of cells by administering an aminosterol compound |
US5874597A (en) * | 1995-06-07 | 1999-02-23 | Magainin Pharmaceuticals, Inc. | Certain aminosterol compounds and pharmaceutical compositions including these compounds |
US5792635A (en) * | 1995-06-07 | 1998-08-11 | Magainin Pharmaceuticals, Inc. | Method of inhibiting the sodium/proton exchanger NHE3 and method of inhibiting growth by administering squalamine |
US5840936A (en) * | 1995-06-07 | 1998-11-24 | Magainin Pharmaceuticals Inc. | Aminosterol compounds useful as inhibitors of the sodium/proton exchanger (NHE) |
US5763430A (en) * | 1995-06-07 | 1998-06-09 | Magainin Pharmaceuticals Inc. | Method of treating a viral infection by administering a steroid compound |
US6143738A (en) * | 1995-06-07 | 2000-11-07 | Magainin Pharmaceuticals, Inc. | Therapeutic uses for an aminosterol compound |
IT1283955B1 (it) * | 1996-03-20 | 1998-05-07 | Sigma Tau Ind Farmaceuti | Bis alcanoil esteri della carnitina ad attivita' antibatterica, antimicotica ed antiprotozoaria. |
US6147060A (en) * | 1996-04-26 | 2000-11-14 | Magainin Pharmaceuticals | Treatment of carcinomas using squalamine in combination with other anti-cancer agents |
US6596712B2 (en) | 1996-04-26 | 2003-07-22 | Genaera Corporation | Treatment of carcinomas using squalamine in combination with other anti-cancer agents or modalities |
US6333189B1 (en) | 1996-06-06 | 2001-12-25 | Alza Corporation | Method of making an electrotransport device |
US6262283B1 (en) | 1996-12-06 | 2001-07-17 | Magainin Pharmaceuticals Inc. | Stereoselective synthesis of 24-hydroxylated compounds useful for the preparation of aminosterols, vitamin D analogs, and other compounds |
IT1299266B1 (it) * | 1998-05-15 | 2000-02-29 | Sigma Tau Ind Farmaceuti | Inibitori reversibili della carnitina palmitoil trasferasi |
PT1274718E (pt) | 2000-04-12 | 2007-01-31 | Genaera Corp | Processo para a preparação de esteróis 7. alfa-hidroxi 3- aminosubstítuidos utilizando intermediários com um grupo 7. alfa-hidroxilo desprotegido |
US7186855B2 (en) | 2001-06-11 | 2007-03-06 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US6818787B2 (en) | 2001-06-11 | 2004-11-16 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
US8048917B2 (en) | 2005-04-06 | 2011-11-01 | Xenoport, Inc. | Prodrugs of GABA analogs, compositions and uses thereof |
EP1902714B1 (de) | 2001-06-11 | 2012-01-11 | XenoPort, Inc. | Prodrugs aus GABA-Analoga, Zusammensetzungen und ihre Verwendungen |
GB0116047D0 (en) * | 2001-06-29 | 2001-08-22 | Implyx Ltd | Peptide motif for therapy |
DE10303669A1 (de) * | 2003-01-28 | 2004-07-29 | Hans-Knöll-Institut für Naturstoff-Forschung e.V. | Tetraalkylammoniumsalze vom Kohlensäureestertyp, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen |
AU2005301970B2 (en) | 2004-11-04 | 2011-06-02 | Arbor Pharmaceuticals, Llc | Gabapentin prodrug sustained release oral dosage forms |
ATE426610T1 (de) * | 2005-02-04 | 2009-04-15 | Us Gov Health & Human Serv | Nandrolon-17ss-carbonate |
US20090238763A1 (en) | 2006-07-09 | 2009-09-24 | Chongxi Yu | High penetration compositions and uses thereof |
US20090221703A1 (en) | 2006-07-09 | 2009-09-03 | Chongxi Yu | High penetration composition and uses thereof |
WO2008013860A2 (en) | 2006-07-28 | 2008-01-31 | Xenoport, Inc. | Acyloxyalkyl carbamate prodrugs of alpha-amino acids, methods of synthesis and use |
EP2084165B1 (de) * | 2006-10-11 | 2013-06-12 | Techfields Biochem Co. Ltd | Positiv geladene, wasserlösliche prodrugs von oxicamen und verwandten verbindungen mit sehr hoher hautpenetrationsrate |
EP2115140B8 (de) * | 2007-01-31 | 2017-01-25 | Chongxi Yu | Positiv geladene wasserlösliche Arzneistoffvorstufen von 1H-Imidazo-[4,5-c]-chinolin-4-aminen und verwandten Verbindungen mit sehr hohen Hautdurchdringungsgeschwindigkeiten |
WO2008099414A1 (en) * | 2007-02-13 | 2008-08-21 | Council Of Scientific & Industrial Research | NOVEL CATIONIC 17 α- SUBSTITUTED-ESTRADIOL DERIVATIVES USEFUL AS ANTI-CANCER AGENT |
JP2010529101A (ja) | 2007-06-04 | 2010-08-26 | テックフィールズ インコーポレイテッド | 非常に速い皮膚及び膜浸透速度を有するnsaiaプロドラッグ及びその新規医薬使用 |
US20110177156A1 (en) * | 2007-11-14 | 2011-07-21 | Szoka Jr Francis C | Sterol-Modified Amphiphilic Lipids |
JP2012511027A (ja) | 2008-12-04 | 2012-05-17 | チョンシー ユー | 高透過性組成物およびその用途 |
JP5732453B2 (ja) | 2009-06-25 | 2015-06-10 | アルカーメス ファーマ アイルランド リミテッド | Nh酸性化合物のプロドラッグ |
PL2445502T5 (pl) | 2009-06-25 | 2023-03-13 | Alkermes Pharma Ireland Limited | Związki heterocykliczne do leczenia zaburzeń neurologicznych i psychologicznych |
ES2857626T3 (es) | 2010-01-15 | 2021-09-29 | Suzhou Neupharma Co Ltd | Ciertas entidades químicas, composiciones y métodos |
CA2802733C (en) | 2010-06-24 | 2017-11-21 | Alkermes Pharma Ireland Limited | Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives |
US9018197B2 (en) | 2010-08-28 | 2015-04-28 | Suzhou Neupharma Co. Ltd. | Tetradecahydro-1H-cyclopenta[a]phenanthrene compounds, compositions, and related methods of use |
EP2670763B1 (de) * | 2011-02-02 | 2018-08-01 | Suzhou Neupharma Co., Ltd | Bestimmte chemische stoffe, zusammensetzungen und verfahren |
CN103561746B (zh) | 2011-03-18 | 2018-05-29 | 奥克梅斯制药爱尔兰有限公司 | 包含脱水山梨糖醇酯的药物组合物 |
ES2779225T3 (es) * | 2011-04-08 | 2020-08-14 | Sphaera Pharma Pte Ltd | Reactivos de merilformilo sustituido y procedimiento de uso de los mismos para modificar propiedades fisicoquímicas y/o farmacocinéticas de compuestos |
WO2013088255A1 (en) | 2011-12-15 | 2013-06-20 | Alkermes Pharma Ireland Limited | Prodrugs of secondary amine compounds |
ES2764383T3 (es) | 2012-03-19 | 2020-06-03 | Alkermes Pharma Ireland Ltd | Composiciones farmacéuticas que comprenden ésteres de glicerol |
US9999670B2 (en) | 2012-03-19 | 2018-06-19 | Alkermes Pharma Ireland Limited | Pharmaceutical compositions comprising benzyl alcohol |
EP2827868B8 (de) | 2012-03-19 | 2019-12-18 | Alkermes Pharma Ireland Limited | Pharmazeutische zusammensetzungen mit fettsäureestern |
WO2013165924A1 (en) | 2012-04-29 | 2013-11-07 | Neupharma, Inc. | Certain chemical entities, compositions, and methods |
NZ748572A (en) | 2012-09-19 | 2020-07-31 | Alkermes Pharma Ireland Ltd | Pharmaceutical compositions having improved storage stability |
CN103896791B (zh) * | 2012-12-25 | 2016-12-28 | 广东隆赋药业股份有限公司 | 乙酰左卡尼汀盐酸盐的制备方法 |
GB201308363D0 (en) | 2013-05-09 | 2013-06-19 | Bagshawe Kenneth D | Tumour therapy |
CA2943213C (en) | 2014-03-20 | 2022-07-05 | Alkermes Pharma Ireland Limited | Aripiprazole formulations having increased injection speeds |
CN104151452B (zh) * | 2014-07-16 | 2017-02-01 | 西北大学 | 聚n‑(2‑羟丙基)甲基丙烯酰胺‑氯尼达明大分子前药及其制备方法 |
CA3092335A1 (en) | 2018-03-05 | 2019-09-12 | Alkermes Pharma Ireland Limited | Aripiprazole dosing strategy |
CN115851076B (zh) * | 2022-12-21 | 2023-10-31 | 湖北航天化学技术研究所 | 一种石墨烯含锌防锈漆及其制备方法 |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3023206A1 (de) * | 1979-11-02 | 1982-01-14 | Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover | Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US4386026A (en) * | 1981-04-20 | 1983-05-31 | Merck & Co., Inc. | Cell-specific glycopeptide ligands |
EP0279887A2 (de) * | 1987-01-15 | 1988-08-31 | Alfred Stracher | Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen |
EP0289262A2 (de) * | 1987-04-27 | 1988-11-02 | Syntex Pharmaceuticals International Limited | Omega-quaternäre Ammoniumalkylester und -thioester von sauren nichtsteroiden entzündungshemmenden Mitteln |
WO1991009831A1 (en) * | 1989-12-26 | 1991-07-11 | Nova Pharmaceutical Corporation | Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use |
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4963367A (en) * | 1984-04-27 | 1990-10-16 | Medaphore, Inc. | Drug delivery compositions and methods |
US5085749A (en) * | 1989-03-14 | 1992-02-04 | Massachusetts Institute Of Technology | Dynamically controlled membrane |
-
1993
- 1993-06-11 EP EP93915319A patent/EP0647133A4/de not_active Withdrawn
- 1993-06-11 AU AU45345/93A patent/AU4534593A/en not_active Abandoned
- 1993-06-11 WO PCT/US1993/005631 patent/WO1993025197A1/en not_active Application Discontinuation
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE3023206A1 (de) * | 1979-11-02 | 1982-01-14 | Efeka Friedrich & Kaufmann GmbH & Co KG, 3000 Hannover | Indometacin-ester, verfahren zu ihrer herstellung und ihre verwendung als arzneimittel |
US4386026A (en) * | 1981-04-20 | 1983-05-31 | Merck & Co., Inc. | Cell-specific glycopeptide ligands |
US5042975A (en) * | 1986-07-25 | 1991-08-27 | Rutgers, The State University Of New Jersey | Iontotherapeutic device and process and iontotherapeutic unit dose |
EP0279887A2 (de) * | 1987-01-15 | 1988-08-31 | Alfred Stracher | Durch Carnitin dirigierte pharmazeutische Substanzen und ihre Verwendung zur Herstellung eines Arzneimittels zur Behandlung von Muskelerkrankungen |
EP0289262A2 (de) * | 1987-04-27 | 1988-11-02 | Syntex Pharmaceuticals International Limited | Omega-quaternäre Ammoniumalkylester und -thioester von sauren nichtsteroiden entzündungshemmenden Mitteln |
WO1991009831A1 (en) * | 1989-12-26 | 1991-07-11 | Nova Pharmaceutical Corporation | Prodrug anhydrides of asprin, indomethacin and ibuprofen, their preparation, compositions, and anti-inflammatory method of use |
Non-Patent Citations (1)
Title |
---|
See also references of WO9325197A1 * |
Also Published As
Publication number | Publication date |
---|---|
WO1993025197A1 (en) | 1993-12-23 |
AU4534593A (en) | 1994-01-04 |
EP0647133A1 (de) | 1995-04-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0647133A4 (de) | Zusammensetzungen und verfahren zur verbesserte arzneimittelabgabe. | |
ZA942804B (en) | Oral drug delivery compositions and methods | |
EP0658111A4 (de) | Verfahren zur steigerung der arzneistoffabgabe mit modifizierten saponinen. | |
IL109661A0 (en) | Drug delivery device | |
EP0662851A4 (de) | ABGABESYSTEM FüR MEDIKAMENTE. | |
GB2271059B (en) | Pharmaceutical compositions comprising aconitane derivatives and tetrahydroprotoberberine derivatives. | |
IL110588A (en) | Bioadhesive emulsion preparations for enhanced drug delivery | |
EP0596962A4 (en) | Therapeutic compositions and methods. | |
EP0491812A4 (en) | Drug delivery compositions | |
EP0676963A4 (de) | Pharmazeutische zusammensetzungen auf der basis von hyaluronsäure und harnstoff und ihre verwendungen. | |
EP0683668A4 (de) | Präparate und verfahren für eine transdermale arzneistoffverabreichung. | |
GB2272375B (en) | Pharmaceutical composition | |
AU1432292A (en) | Drug delivery composition and method of using the same | |
GB9325330D0 (en) | Fluorocyclodextrin drug delivery system | |
EP0600754A3 (de) | Pharmazeutische Infusionseinrichtung mit konstantem Durchfluss. | |
GB9404293D0 (en) | Drug delivery system | |
ZA937405B (en) | 3-substituted 2-oxindole-1-carboxamide pharmaceutical compositions | |
EP0636363A3 (de) | Verabreichungssystem für Arzneistoffe. | |
GB2292887B (en) | Drug delivery system | |
GB9223363D0 (en) | Drug etc.delivery | |
ZA931775B (en) | Drug delivery devices. | |
GB9303117D0 (en) | Drug delivery system | |
GB9324682D0 (en) | Drug delivery system | |
GB9307904D0 (en) | Drug delivery system | |
ZA93286B (en) | Pharmaceutical compositions. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PUAI | Public reference made under article 153(3) epc to a published international application that has entered the european phase |
Free format text: ORIGINAL CODE: 0009012 |
|
17P | Request for examination filed |
Effective date: 19950112 |
|
AK | Designated contracting states |
Kind code of ref document: A1 Designated state(s): CH DE FR GB IT LI NL |
|
RHK1 | Main classification (correction) |
Ipc: A61K 47/48 |
|
A4 | Supplementary search report drawn up and despatched | ||
AK | Designated contracting states |
Kind code of ref document: A4 Designated state(s): CH DE FR GB IT LI NL |
|
17Q | First examination report despatched |
Effective date: 19980120 |
|
STAA | Information on the status of an ep patent application or granted ep patent |
Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN |
|
18D | Application deemed to be withdrawn |
Effective date: 19980603 |